ABSTRACT

Introduction: Patients with head and neck cancer (HNC) are usually confronted with functional changes due to the malignancy itself or its treatment. These factors typically affect important structures involved in speech, breathing, chewing, swallowing, and saliva production. Consequently, the intake of food will be limited, which further contributes to loss of body weight and muscle mass, anorexia, malnutrition, fatigue, and anemia. This multifactorial condition can ultimately lead to cancer cachexia syndrome. This study aims to examine the treatment of cachexia in HNC patients.

Methods: We systematically searched OvidMedline, PubMed, Scopus, and Web of Science for articles examining the treatment of cachexia in HNC.

Results: A total of nine studies were found, and these suggested interventions including nutritional, pharmacologic, therapeutic exercise, and...
multimodal approaches. The nutritional intervention includes essential components such as dietary counseling, oral nutritional supplements, and medical nutritional support. Individualized nutritional interventions include oral, enteral (feeding tubes i.e., percutaneous endoscopic gastrostomy [PEG], nasogastric tube [NGT]) and parenteral nutrition. The pharmacologic interventions aim at increasing the appetite and weight of cachectic patients. Therapeutic exercise and increased physical activity can help to enhance the synthesis of muscle protein, reducing inflammation and the catabolic effects of cachexia syndrome.

**Conclusion:** Owing to the multifactorial nature of this syndrome, it is expected that the management approach should be multi-interventional. Early implementation of these interventions may help to improve survival and quality of health and life of cachectic HNC patients.

**Keywords:** Anorexia; Cachexia; Head and neck cancer; Systematic review; Sarcopenia

### Key Summary Points

Head and neck cancer (HNC) patients frequently suffer from cachexia, which is a multifactorial condition that can affect the treatment outcome and quality of life of these patients.

The management approach of HNC-related cachexia should be multi-interventional because of the multifactorial nature of the syndrome.

---

F. López - J. P. Rodrigo  
Department of Otolaryngology-Head and Neck Surgery, Hospital Universitario Central de Asturias, University of Oviedo, ISPA, IUOPA, CIBERONC, Oviedo, Spain

R. de Bree  
Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

A. Ferlito  
Coordinator of the International Head and Neck Scientific Group, Padua, Italy

---

The optimal approach would include preventive measures and early diagnosis of this condition. Additionally, novel technology carries the potential to aid in recognizing and monitoring early signs of cachexia.

Awareness of this entity (cachexia) needs to be raised among both surgical and oncologic caregivers. To perform the required clinical research, the standard for clinically applicable score for cachexia classification and assessment should be defined.

In the future, individualized treatment options that can be offered for this patient population should be explored.

---

**INTRODUCTION**

Cancer may be associated with pain, psychologic distress, disfiguration, dysfunction, malnutrition, metabolic changes, and ultimately death [1]. It is the second leading cause of death worldwide and can affect any part of the body including the head and neck region [2]. In the USA, head and neck cancer (HNC) accounts for 3% of new cases for all cancers and 1.5% of all cancer deaths [3, 4]. Furthermore, HNC was ranked as one of the most common cancers globally in 2018 [1].

Several recent advancements in the treatment planning and management of HNC include minimally invasive procedures, transoral robotic surgery, organ-sparing surgical procedures, advancements in radiotherapy, and curative multimodal treatment including immune-checkpoint inhibitors [1]. All of these are targeted at reducing morbidity, mortality, and physical and psychologic changes while preserving the daily function that can enhance improved quality of life of HNC patients. HNC patients frequently suffer from dysphagia and anorexia because of the tumor growth itself and/or treatment-related side effects or anxiety as to the possible outcome of treatment [5]. Consequently, malnourishment and weight loss
### Table 1 Main findings in the included studies

| Study/type of study | Location | Title of the study                                                                 | Size of the series (methodology) | Intervention                                                                 | Conclusion                                                                 |
|---------------------|----------|-----------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Mantovani et al. [23]/ original study | Italy | A phase II study with antioxidants, both in the diet and as supplemented pharmaconutritional support, progestogen, and anti/cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress | 39                               | Integrated treatment: Pharmaconutritional support                            | Body weight, lean body mass, and appetite increased significantly          |
|                     |          |                                                                                   |                                  |                                                                               | Improved quality of life                                                  |
|                     |          |                                                                                   |                                  |                                                                               | The intervention was effective and safe                                   |
| Lai et al. [24]/ original study | US | Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract | 11 (4 for celecoxib-treated patients, 7 for placebo-treated patients) | Pharmacologic intervention—celecoxib                                      | Patients that received celecoxib experienced noticeable increase in weight and body mass index |
|                     |          |                                                                                   |                                  |                                                                               | The weight and body mass index in the placebo group decreased             |
|                     |          |                                                                                   |                                  |                                                                               | A moderate dose of celecoxib for cachectic patients may help in the quest to manage cachexia and improve quality of life score in cancer cachectic patients. This approach may also improve the outcome of cancer therapy |
| Study/type of study | Location | Title of the study | Size of the series (methodology) | Intervention | Conclusion |
|---------------------|----------|--------------------|----------------------------------|--------------|------------|
| Mantovani et al. [25]/ randomized controlled trial | Italy | Randomized phase III clinical trial of five different arms treatment in 332 patients with cancer cachexia | 332 | Pharmacologic intervention—Medroxyprogesterone, megestrol acetate, L-carnitine, thalidomide Nutritional intervention—oral supplement with eicosapentaenoic acid Multi-interventional—combination of the aforementioned pharmacologic and nutritional interventions | Patients that received multi-interventional treatment (arm 5) showed the best treatment outcome |
| Arm 1 (n = 44): patients received medroxyprogesterone | | | | | |
| Arm 2 (n = 25): patients were given oral supplement | | | | | |
| Arm 3 (n = 88): only L-carnitine was given to the patients | | | | | |
| Arm 4 (n = 87): thalidomide was given to the patients | | | | | |
| Arm 5 (n = 88): combination of the above-mentioned arms | | | | | |
| Madeedu et al. [26]/ randomized controlled trial | Italy | Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome | 60 | Pharmacologic intervention—1. Arm (1) two-drug combination. Arm (2) two-drug combination + megestrol acetate Antioxidants | There was no significant different between the two arms |
| Study/type of study | Location | Title of the study | Size of the series (methodology) | Intervention | Conclusion |
|---------------------|----------|--------------------|----------------------------------|--------------|------------|
| Yeh et al. [27]     | Taiwan   | Omega-3 fatty acid, micronutrient, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia | 68 (31 patients received Ethanwell regimen, 37 patients received Isocal) | Nutritional intervention—Omega-3 fatty acid, micronutrient, and probiotic-enriched nutrition | Increased body weight and higher serum albumin and pre-albumin were observed in patients that received Ethanwell regimen. HNC patients with body mass index < 19 may benefit from EE regimen. |
| Grote et al. [28]   | Germany  | Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial | 20 cachectic patients ($n = 10$ received machine-supported progressive resistance training, $n = 10$ received usual care) | Progressive resistance training is an exercise-oriented training. The training took place 3 x in a week for 30 min. | Progressive resistance training in cachectic HNC patients seems to be safe and posited to be beneficial for general fatigue and quality of life. |
| Bar-Sela et al. [29] | Israel   | The effects of dose-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study | 24 patients (17 started but 11 received capsules for more than 2 weeks) | Pharmacologic intervention | The cannabis capsule treatment led to increase in weight of the patients. |
| Study/type of study | Location | Title of the study | Size of the series (methodology) | Intervention | Conclusion |
|---------------------|----------|-------------------|-------------------------------|--------------|------------|
| Osmolak et al. [30] randomized controlled trial | USA | Does perioperative oxandrolone improve nutritional status in patients with cachexia related to head and neck carcinoma? | 18 perioperative | Oxandrolone (perioperative administration of oxandrolone) Appropriate dose of oxandrolone for 10 days may be useful in perioperative care of nutritional deficiency in HNC patients | The perioperative administration of oxandrolone showed improvement in prealbumins level and subjective improvements in surgical wounds |
| Blum et al. [31] a case series | Switzerland | Natural ghrelin in advanced cancer patients with cachexia, a case series | 10 (6 received allocated intervention, 4 did not receive) | Nutritional intervention—ghrelin | Natural ghrelin has a positive effect on the nutritional intake of cachectic patients |

*Advanced stage solid cancers including head and neck cancer*
are typically observed. Among HNC patients receiving radiotherapy (RT), severe weight loss was seen prior to RT in 3% and at the end of RT in 44% of patients, while the frequency of malnutrition increased from 3% up to 88% [6, 7].

Cachexia (or anorexia-cachexia syndrome) is a complex metabolic syndrome in which systemic inflammation is the key feature and weight loss (e.g., ≥5% of body weight during the past 6 months) is the key diagnostic criterion. Cachexia can be an underlying condition in patients with sarcopenia. Anorexia is characterized by decreased food intake because of treatment side effects and depression, and it manifests as reduced energy intake and involuntary weight loss in these patients [5]. Cachexia can be defined as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Cachexia is primarily associated with a particular underlying condition such as uncontrollable tumor growth that leads to extreme loss of appetite and weight and systemic signs of inflammations [5, 8–11]. When it affects oncologic patients, it is known as cancer cachexia (cancer-induced cachexia) [12]. In this case, there is a loss of appetite due to metabolic alterations associated with cancer. Thus, the quality of life and health of these patients are affected due to the cancer itself and increased by treatment-related toxicity [13] causing poor survival [14]. Weight loss can be associated with loss of muscle mass and function (e.g., strength), and this is referred to as sarcopenia. Sarcopenia was first thought to be a physiologic state in the elderly; however, scientific research has changed the perception of the condition and uncovered myriad causes. Sarcopenia can be the result of cancer cachexia, and it has been associated with adverse treatment outcome in HNC patients [15].

Among HNC patients, cachexia is more pronounced as this cancer affects the functional structures of the human body that are directly involved in nutritional intake. As a result, deglutitive and masticatory functions are affected resulting in a deterioration of nutritional status.
In addition, patients may become vulnerable to infection, fatigue, pain, and dyspnea. All these may contribute further to weight loss and have a negative effect on functional and survival prognoses [16]. As sarcopenia is primarily a functional condition, the patients with cachexia experience negative changes in metabolic functioning, loss of appetite, loss of adipose tissue, wasting of tissues, and loss of skeletal muscle mass.

We systematically reviewed the published studies on the treatment of cachexia in HNC. It was our primary aim to explore the scientific evidence on the preventive approaches and management of cachexia in this patient population.

### METHODS

#### Search of Databases and Study Period

We systematically searched OvidMedline, PubMed, Scopus, and Web of Science databases from inception until 15 October 2021 to retrieve all studies addressing cachexia in HNC.

#### Search Terms

The potentially relevant articles were retrieved by combining search keywords: [‘cachexia OR sarcopenia’) AND (‘head and neck cancer’)].

#### Search Analysis

The search analysis was done using RefWorks web-based bibliography and database manager. All the retrieved potentially relevant articles were exported to RefWorks for further analyses. The hits were further analyzed for possible duplicates and irrelevant studies. The inclusion and exclusion criteria were defined based on the study-specific research questions.

#### Inclusion and Exclusion Criteria

All studies that had examined the treatment interventions of cachexia or sarcopenia in HNC were included. Considering the need to gather important information and to reduce research waste regarding cachexia and its management in head and neck cancer, systematic reviews on cachexia in HNC were included in this study. Furthermore, studies with no specific mention of a cancer site were considered in this review to check if they included general treatment interventions for cachexia. As the number of relevant studies appeared limited, a scoping review approach was applied. To minimize the omission of any potential study, the reference lists of all the potentially eligible articles were manually searched to ensure that all the relevant studies were adequately included. Comments, opinions, perspectives, guidelines, editorials, and articles in languages other than English were excluded. All articles about the

| Study               | Oxford quality scoring system | Quality interpretation |
|---------------------|-------------------------------|------------------------|
| Mantovani et al. [23] | 3                             | High                   |
| Lai et al. [24]     | 5                             | High                   |
| Mantovani et al. [25] | 4                             | High                   |
| Madeddu et al. [26]  | 5                             | High                   |
| Yeh et al. [27]     | 5                             | High                   |
| Grote et al. [28]   | 4                             | High                   |
| Bar-Sela et al. [29] | 2                             | Low                    |
| Osmolak et al. [30]  | 3                             | High                   |
| Blum et al. [31]    | 3                             | High                   |

Table 2: Summary of quality assessment using the Oxford quality scoring system (Jadad scale)
Table 3 Tool for assessing the risk of bias (adapted from Higgins et al. 2011)

| Bias domain     | Source of bias               | Support for judgment                                                                 |
|-----------------|-----------------------------|--------------------------------------------------------------------------------------|
| Selection bias  | Random sequence generation  | State how the cachectic patients were selected in sufficient detail to allow an assessment of whether it should produce comparable groups |
|                 | Allocation concealment      | Describe the control group (groups that did not receive cachectic intervention) or compare between interventions in sufficient detail to determine whether intervention allocations were effective during enrollment |
| Performance bias| Blinding of participants⁴  | State all measures used, if any, to prevent trial participants from having the knowledge of which intervention they received |
| Detection bias  | Blinding of outcome assessment⁴ | State all measures used, if any, to prevent influence of the knowledge of intervention received on the outcome assessment |
| Attrition bias  | Incomplete outcome data⁴  | Describe the completeness of outcome data for each endpoint, including incomplete and excluded participants from the analysis |
| Reporting bias  | Selective reporting         | State how the endpoint reporting was done and what was the conclusion                |
| Other biases    | Anything else, ideally prespecified | Other biases not covered elsewhere in the examined domains. For example, the inclusion of other tumors besides head and neck cancer in the analysis |

⁴Assessments made for each main outcome (endpoint)

Table 4 Presentation of risk of bias assessments for the included studies

| Study                      | Random sequence generation | Allocation concealment | Blinding of participants | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other biases |
|----------------------------|---------------------------|------------------------|--------------------------|-------------------------------|-------------------------|---------------------|-------------|
| Mantovani et al., 2006     | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Lai et al., 2008            | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Mantovani et al., 2010      | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Madeeddu et al., 2012       | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Yeh et al., 2013            | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Grote et al., 2018          | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Bar-Sela et al., 2019       | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Osmolak et al., 2019        | Low risk                  | Low risk               | Low risk                 | Low risk                      | Low risk                | Low risk            | Low risk     |
| Blum et al., 2021           | Low risk                  | Low risk               | High risk                | Low risk                      | Low risk                | Low risk            | Low risk     |

Low risk  🟢, Unclear risk  🟦, High risk  🟤
### Table 5 Included studies and the examined endpoints

| S/N | Studies               | Examined endpoints | Intervention                                      | Duration of intervention | Results                                                                 |
|-----|-----------------------|--------------------|--------------------------------------------------|--------------------------|-------------------------------------------------------------------------|
| 1   | Mantovani et al. [23]/ original study<sup>a</sup> | Body weight        | Pharmacologic intervention                       | 12 weeks                 | 500 mg/day medroxyprogesterone acetate; 200 mg/day celecoxib; 2.2 g/day eicosapentaenoic acid or 0.9 g/day docosa hexaenoic acid; antioxidant These improved the following endpoints: Improved quality of life Increased appetite |
|     |                       | Lean body mass     |                                                  |                          |                                                                         |
|     |                       |                    |                                                  |                          |                                                                         |
| 2   | Lai et al. [24]/ original study | Body weight        | Pharmacologic intervention—celecoxib            | 21 days                  | Patients that received celecoxib showed: Increase in body weight Increase in body mass index Increased quality of life score |
|     |                       | Body mass index    |                                                  |                          |                                                                         |
|     |                       | Quality of life    |                                                  |                          |                                                                         |
| 3   | Mantovani et al. [25]/ original study<sup>a</sup> | Primary endpoints: | Pharmacologic intervention—Nutritional intervention | 4 months                 | A combination of 500 mg/day of medroxyprogesterone or 320 mg/day + oral supplement with eicosapentaenoic acid + 4 g/day of L-carnitine + 200 mg/day of thalidomide improved the following endpoints: Improved lean body mass Increased appetite Interleukin (IL)—6 decreased significantly Toxicity reduced |
|     |                       | Lean body mass     | Hybrid regimen: combination of pharmacologic and nutritional interventions |                          |                                                                         |
|     |                       | Decrease in resting energy expenditure |                                                  |                          |                                                                         |
|     |                       | Decrease in fatigue |                                                  |                          |                                                                         |
|     |                       | Secondary endpoints: |                                                  |                          |                                                                         |
|     |                       | Appetite           |                                                  |                          |                                                                         |
|     |                       | Quality of life    |                                                  |                          |                                                                         |
|     |                       | Grip strength      |                                                  |                          |                                                                         |
| S/N | Studies | Examined endpoints | Intervention | Duration of intervention | Results |
|-----|---------|--------------------|--------------|-------------------------|---------|
| 4   | Madeddu et al. [26]/ original study | - Primary endpoints:  
  - Lean body mass  
  - Physical activity  
  - Secondary endpoints:  
  - Physical performance  
  - Grip strength  
  - Walk test | Pharmacologic intervention | 4 months | 4 g/day  
  L-carnitine + 300 mg/day  
  celecoxib ± 320 mg/day  
  megestrol acetate  
  Improved physical function  
  Fatigue  
  Improved performance  
  Appetite |
| 5   | Yeh et al. [27]/ original study | - Body weight  
  - Serum albumin level  
  - Albumin level | Nutritional intervention—ethanwell/ethenzyme (EE) regimen enriched with Omega-3 fatty acid, micronutrient, and probiotic-enriched nutrition or control (Isocal) for 3 months period | 3 months | Patients with body mass index < 19 showed improved body weight  
  Higher serum albumin levels  
  Higher prealbumin level  
  The increase in body weight was associated with increased serum albumin and prealbumin level |
| 6   | Grote et al. [28]/ randomized controlled trial | - Fatigue (body weight)  
  - Quality of life | Exercise (progressive resistance training) | 15 weeks (7 weeks of radiotherapy and 8 weeks after radiotherapy) | Less fatigue was observed  
  Improved quality of life |
pathophysiology, pathogenesis, assessments, overview, effects, definitions, and diagnostic features of cachexia or sarcopenia were excluded. Similarly, studies that focused on anorexia, dysphagia, or mucositis, or mainly on nutritional support in cancer patients, were excluded. All studies that examined cachexia in animals were excluded.

### Search Reporting and Screening

Two independent researchers (R.A. and O.Y) performed the screening of potentially relevant articles and used a data extraction sheet to minimize the omission of possible eligible studies. Possible discrepancies were resolved by discussion until a consensus was reached. Thus, the interobserver reliability between the two independent researchers was measured using Cohen’s kappa coefficient ($k = 0.94$). All eligible studies to be included are summarized in Table 1. The reporting of the search protocols (searching and screening processes) is given using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) (Fig. 1). This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and followed the PRISMA guidelines in the review process. As this study is a systematic

### Table 5 continued

| S/ N | Studies Examined | Intervention | Duration of intervention | Results |
|------|------------------|--------------|--------------------------|---------|
| 7    | Bar-Sela et al. [29]/original study$^a$ | Primary endpoints: Body weight Secondary endpoints: Appetite Reduction in pain and fatigue Grip strength | Pharmacologic intervention—(tetrahydrocannabinol and cannabidiol) | 6 months | Weight increase of 10% in patients that received 5 mg $\times 1$ or 5 mg $\times 2$ capsules daily Improvement in appetite and mood Reduction in pain and fatigue |
| 8    | Osmolak et al. [30]/randomized controlled trial | Prealbumin levels Surgical wounds | Nutritional intervention—oxandrolone | 10 days | 10 mg twice a day: Improvement in prealbumin levels Improvement in surgical wounds |
| 9    | Blum et al. [31]/case series$^a$ | Muscle mass Appetite | Nutritional intervention—ghrelin | 4 days (twice/day). Then, 6 weeks of maintenance period (10 doses/week) | 32 $\mu$g/kg of body weight: improved appetite and eating-related symptoms Stable muscle mass and strength |

$^a$Advanced stage solid cancers including head and neck cancer
A scoping review, ethical review and informed consent were not required.

Quality Appraisal

As this study considered original studies and randomized controlled trials as eligible studies, two different quality appraisal paradigms were used. The quality of the included studies was initially appraised using the quality guideline for systematic review as recommended by the National Institute of Health Quality Assessment tools [17]. These studies were subjected to four quality criteria informed by the same quality assessment tool [18]. These criteria were modified to include design, methodology, interventions, and statistical analysis. The studies that showed reasonable quality (≥ 50%) from this initial quality assessment were further subjected to the Oxford quality scoring system, also known as the Jadad scale. The Jadad quality assessment scale is a representative quality assessment tool that is suitable for systematic review that includes randomized controlled trials. It is an easy-to-use scale with known reliability and external validity and important elements that have empirically been shown to correlate with bias [19]. Based on this scale, the maximum attainable score was 5 points; two in relation to randomization, two in relation to blinding, and one in relation to the dropout rate [20, 21]. An overall score ≥ 3 indicated ‘high’ quality. Conversely, a Jadad scale score of ≤ 2 was defined as ‘low’ quality (Table 2) [20]. The quality assessment was followed by the risk of bias analysis of the included studies.

![Fig. 2 Management interventions of cachexia](image)

Fig. 2 Management interventions of cachexia

![Fig. 3 Understanding precachexia, cachexia, and refractory cachexia](image)

Fig. 3 Understanding precachexia, cachexia, and refractory cachexia
using the Cochrane collaboration risk of bias tool ("Risk of Bias Analysis").

Risk of Bias Analysis

We used the Cochrane Collaboration’s tool for assessing the risk of bias of the included studies. This tool was modified from Higgins et al. (2011) to properly examine the risk of bias in this study [22]. The modified bias domains appear summarized in Table 3. The details of the bias analysis and the corresponding results from each examined bias are presented in Table 4.

Data Extraction

In each eligible study, the first author’s name, year of publication, country, title of the study, number of the participants in the study or number of studies reviewed, site of cancer considered, suggested interventions or cachexia management, and summary of the study were extracted (summarized in Table 1). The detailed explanation of the strategic interventions to manage cancer cachexia in HNC patients is discussed collectively in the Discussion section. Based on the summary of the included studies (Table 1), the endpoints examined through randomized control trials, case series, and original studies included in this systematic scoping review are specifically discussed in this study and summarized in Table 5.

RESULTS

Results of the Database Search

A total of 1978 hits were retrieved. After deleting duplicates (N = 580), irrelevant papers (N = 1357), and exclusions (N = 32), we found nine studies eligible to be included in this scoping review as shown in Fig. 1 [23–31].

Characteristics of Relevant Studies

All the articles included were published in the English language. The quality assessment of the included studies showed that eight (88.9%) showed high-quality assessment scores [23–28, 30, 31]. Likewise, only a single study (14.3%) of the included studies had a low-quality score (Table 2) [29]. In terms of the risk of bias, all the included studies showed low risk of bias in the selection of cachectic patients, analysis of the cachectic intervention and endpoint evaluation, and reporting of outcome of these interventions (Table 4). Similarly, six out of the nine studies showed a low risk of unreliability of the examined interventions by comparing the outcome of the various intervention groups and those that received either placebo or no intervention at all [24–28, 30] (Table 4). However, only one study had a high risk of bias regarding the evaluated cachexia intervention because a reasonable number of the participants did not complete the study [29]. Additionally, four studies included other advanced stage solid cancers alongside head and neck cancer, which may include other biases in terms of the actual efficacy of the intervention [23, 25, 26, 29].

Of the nine included studies, five (55.6%) had been carried out in Europe [23, 25, 26, 28, 31] and two (22.2%) studies each in the US [24, 30] and Asia [27, 29]. From the included studies, two (22.2%) recommended both nutritional and pharmacologic interventions for the management of cachexia in HNC patients [23, 25]. Three (33.3%) studies each suggested only either nutritional intervention [27, 30, 31] or pharmacologic intervention [24, 26, 29]. Similarly, only one study (14.3%) suggested other emerging interventions in addition to the nutritional and pharmacologic interventions such as exercise or resistance training [28]. Of note, it was suggested that a multi-modal/multi-interventional approach that consists of pharmacologic, nutritional, and other targeted interventions is poised to be the most effective treatment in terms of the targeted endpoints of lean body mass, resting energy expenditure, fatigue, appetite, quality of life, and grip strength [25] (Fig. 2).
**Summary of the Findings from the Relevant Studies**

The findings of these studies (summarized in Table 1) indicate that cancer cachexia is associated with weight loss, poor nutritional status, and systemic inflammation. Cancer cachexia can thus predict a poor treatment outcome in patients with HNC. The primary endpoints examined for cachexia intervention in some of the included studies in this systematic scoping review were lean body mass, body weight, resting energy expenditure, fatigue, serum albumin level, prealbumin level, and body mass index [23–31] (Table 5). Likewise, the highlighted secondary endpoints for cachexia interventions were appetite, quality of life, reduction in pain, grip strength, physical performance, walk test, and surgical wounds [24–26, 28, 29, 31] (Table 5).

Hybrid regimens that include a combination of pharmacologic and nutritional interventions led to increase in lean body mass and decrease in resting energy expenditure and fatigue [25]. Similarly, hybrid regimens were also found to be potent interventions for cachectic endpoints of improved appetite, grip strength, and quality of life [25]. Besides hybrid interventions, pharmacologic interventions such as medroxyprogesterone, megestrol acetate, l-carnitine, celecoxib, thalidomide, tetrahydrocannabinol, and cannabidiol have shown promising results regarding their respective target endpoints of increased body weight, pain and fatigue reduction, improved grip strength, and improved quality of life [24, 25, 29]. Of note, only two of the pharmacologic interventions were found to be widely used and approved in Europe. These are progestational agents such as medroxyprogesterone acetate or megestrol acetate and corticosteroids [23, 25, 26, 32–35]. For nutritional interventions, nutraceuticals, nutritional support, cyproheptadine, amino acid loading, curcumin, resveratrol, pomegranate, and other interventions such as physical activity were suggested [32, 36–38]. The use of pharmacologic interventions such as cyproheptadine, hydrazine, metoclopramide, and pentoxifylline was found to be ineffective in one study [39]. The interventional ability of some pharmaceutical drugs such as eicosapentaenoic acid, cannabinoids, and bortezomib was reported to have failed or produced equivocal results [39]. Thus, the discussion section of the present review focuses on interventions with promising results in the defined endpoints.

**DISCUSSION**

Cachexia is defined as a multifactorial syndrome characterized by the ongoing loss of skeletal muscle mass with loss of fat mass [11]. Nutritional support and therapy cannot fully reverse the condition of cachexia, and this will lead to reduced physical function [11]. It has been reported that higher energy intakes would be necessary in patients treated for HNC to maintain skeletal muscle mass [40]. Pathophysiologically, cachectic HNC patients have...
reduced food intake and abnormal metabolism [11]. Precachexia is recognized by early clinical and metabolic signs that precede substantial weight loss, i.e., > 2% and < 5% [54]. This state is usually overlooked as an early stage of cachexia. It usually begins with a slight weight loss that occurs involuntarily. Nonetheless, metabolic changes and inflammations occur at this stage. While cachexia is the main condition considered in the present study, refractory cachexia is a clinically resistant catabolic state [10] (Fig. 3). Hence, it is a more severe syndrome with a low World Health Organization performance status score, an irremissiveness to anticancer therapy, and a survival period of < 3 months [12] (Fig. 3).

A concerted effort is still ongoing to obtain a consensus on the diagnostic standard for refractory cachexia [10]. Of note, the patients progress from one stage to the other if timely and necessary interventions are not introduced [10] (Fig. 3). The chance of progression depends on factors such as the HNC subsite and stage, food intake, level of patient activity, irresponsiveness to anticancer treatment, and/or treatment-related sequelae and complications [10]. Therefore, early recognition of cachexia is important because cachectic patients have higher rates of postoperative complications and infections and impaired response to adjuvant treatment and thus poor quality of life and higher mortality rates [5, 41, 42]. Similarly, early initiation of aggressive nutrition intervention with multimodal approach improves outcomes by helping to maintain patient on the intended treatment regimen with fewer changes [43, 44]. Most importantly, cachexia syndrome should be taken into significant consideration for the effective development of practice guidelines, and ultimately, and routine clinical management of HNC patients.

Several attempts have been made to obtain unanimous consensus on a diagnostic benchmark for cancer cachexia [9, 11, 45]. The most widely presented criteria in the published studies include weight loss > 5% in the previous 6 months or weight loss > 2% in individuals already showing depletion according to current body mass index < 20 kg/m²) or reduced skeletal muscle mass (sarcopenia) [11, 46]. Of note, it has been observed that muscle mass depletion is common in HNC patients with cachectic syndrome [47].

Chemotherapeutic, radiotherapeutic, and surgical complications in HNC cachectic patients have resulted in a low survival rate [5]. Weight loss remains the primary reason, and it is one of the main features of a cachectic HNC patient. Thus, lowering the doses of (chemo)radiotherapy does not seem to be helpful for improving overall survival because of the severe weight loss [48, 49]. Therefore, weight loss has been found to be a detrimental factor hindering the proper management of cachectic HNC patients [5].

The generally accepted principal for the management of cachexia is based on early commencement of individualized nutrition with sufficient protein and energy intake with sufficient symptom management. Despite the advancements in diagnostic and treatment methods for HNC, little or no active attention is usually given to the recognition, assessment, and management of cachexia in this patient population [50–52]. Therefore, it seems to represent an unmet impending factor that can hinder maximizing the intended clinical benefits from multimodality treatment aimed at improving quality of health and chance of survival in HNC patients [53, 54]. Although cachexia has been well recognized as a disease condition, it deserves attention because of its potential to contribute to the mortality rate in patients with cancer [5].

This systematic review presents a scoping approach examining the published studies on management of cachexia in head and neck cancer (HNC) patients. The indices of cachexia include lean body mass, resting energy expenditure, fatigue, loss of appetite, reduced grip strength, inflammation, and impaired quality of life [25]. First, we found that cachexia has adverse effects on both functional (impaired quality of life and quality of health, increased healthcare expenses) and survival (cancer-related death) prognoses of cancer. Second, pharmacologic [24, 26, 29], nutritional [27, 30, 31], and therapeutic exercise (resistance training) [28] are the interventions suggested for managing cachexia in HNC patients (Fig. 2).
However, for optimal management of cachexia, a combination of these interventions, i.e., a multi-interventional approach, is recommended because of the multifactorial nature of the syndrome [23, 25, 32, 37–39, 55].

Considering weight loss as one of the indicators of cancer cachexia in HNC patients, nutritional interventions, including nutritional counseling and support, and supplemental interventions are poised to offer an effective management approach for this syndrome. For example, an oral nutrition supplement, like the ethanwell/ethanzyme (EE) regimen, which was enriched with omega-3 fatty acids, micronutrients, and probiotics, was found to enhance body weight stabilization in HNC cachectic patients [27]. The levels of serum albumin and pre-albumin in these patients were found to be significantly increased [27]. A similar study further emphasized the importance of a multi-targeted (multi-interventional) approach by combining dietary micronutrients such as omega-3 fatty acids with pharmacologic intervention. This combination was reported to improve fatigue and lean body mass [25].

The weight of HNC patients should be monitored and recorded during the disease trajectory for early detection of cachexia. Consequently, nutrition counseling by registered dietitian and individualized nutrition support aimed at improving weight loss and physical functions should be introduced. This will improve quality of health and aid in achieving the touted benefits from the cancer treatment. Because HNC and its treatment have the potential to affect the route of food intake, nutrition is usually administered to HNC patients through enteral route, i.e., percutaneous endoscopic gastronomy (PEG), or nasogastric tube (NAG). Parenteral feeding is prescribed only for patients with nonfunctional or inaccessible enteral route [5]. This insightful approach to nutrition administration has been reported to help patients with less weight loss, improved quality of life, and survival rate [5, 25, 27, 56]. In addition, numerous guidelines have been suggested for the proper nutritional assessment, monitoring, and management of HNC cachectic patients [57]. Similarly, numerous articles have been published on the importance of nutritional interventions [58].

Beyond the spectrum of nutritional intervention is pharmacologic intervention in the management of cachexia in HNC patients. This pharmacologic intervention can be divided into two main categories based on the intended aim of this intervention. First, these are drugs that increase appetite (i.e., appetite stimulants) in cachectic HNC patients. For instance, glucocorticoids, progestagens (medroxyprogesterone and megestrol acetate [megace]), glucodexamethasone, and orexigenic agents (dronabinol, pentoxifylline, nandrolone, nutritional pharmacomodulation [omega-3 fatty acids], etc.) have been used to increase appetite in cachectic HNC patients [23, 27]. Second, other pharmacologic interventions include nonsteroidal anti-inflammatory and anticytokine drugs and antioxidant agents [5]. Examples of these drugs include celecoxib and thalidomide [5, 24, 26]. Of note, it is important to have a multimodal approach to these pharmacologic interventions to achieve the best outcomes [5, 23, 25]. Therefore, the onus is on the caregivers to evaluate the individualized situation of cachectic HNC patients for the best combination of pharmacologic therapy (multinutrient or multitarget) for improved body weight and appetite and reduced inflammation.

Therapeutic exercise and increased physical activity are thought to be beneficial for cachectic HNC patients [28, 59]. As cachexia is associated with inflammation and anemia, the potential of muscle pain and weakness increases. However, exercise therapy can help to enhance the synthesis of muscle protein. Additionally, it can reduce the catabolic effects of cachexia syndrome and the extent of inflammation. This is poised to offer a non-pharmacologic treatment of HNC cachectic patients to improve physical functions and quality of life [5, 28, 60]. Considering the condition of HNC cachectic patients, physical exercise may not be feasible. Thus, an alternative exercise paradigm such as neuromuscular electrical stimulation (NEMS) may be considered to strengthen the muscles [5].

This systematic scoping review emphasizes that the assessment and management of
cachexia in HNC patients constitute major challenges for clinicians [10]. The standard for a clinically applicable score for cachexia classification and assessment should be defined. The standard endpoints (primary and secondary) for cancer-induced interventions should be highlighted. Similarly, the assessment tool for these endpoints should be defined. The most effective interventional approaches should be properly evaluated. Even though there are neither effective medical interventions nor approved drugs to completely reverse cachexia [61], major caregivers such as oncologic nurses and clinicians have an important role in the proper management of cachectic HNC patients. For instance, an oncologic nurse should be vigilant for the early signs of cachexia for prompt intervention [5, 62]. This includes being active in the routine assessment of the dietary habits of patients, nutritional components (status, deficiencies, and possible interventions), weight monitoring, swallowing and chewing activities, and oral care of the HNC patients. Similarly, the oncologist should offer an open and approachable relationship with other members of the team to ensure that necessary interventions will be introduced from the onset. The future management of cachexia will need to consider combining sufficient nutritional intake, physical exercise and inflammation reducing and protein synthesis increasing medical treatment.

In conclusion, increasing muscle volume and decreasing inflammation remain crucial components of cachexia management. However, feasible and partly novel approaches to enhance the effective management of HNC-induced cachexia warrant further studies. Additionally, cachexia assessment should be employed as a routine part of the management of HNC. Considering the adverse effects of this syndrome on the quality of health and chance of survival, it is important that a standard of care regarding the available interventions should be considered by the concerned authorities and organizations.

ACKNOWLEDGEMENTS

**Funding.** Open Access funding provided by University of Helsinki including Helsinki University Central Hospital. The Sigrid Jusélius Foundation. The Helsinki University Hospital Research Fund. The Turku University Hospital Research Fund. The University of Helsinki Library funded the Open Access fees for the publication of this study. No funding or sponsorship was received for the journal’s rapid service fee for this article.

**Medical Writing, Editorial and Other Assistance.** The authors thank Dr. Carl Silver for his valuable editing of the English of the manuscript.

**Authorship.** All mentioned authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Author Contributions.** The study was conceived and designed by Antti Makitie. Alabi Rasheed and Omar Youssef performed the literature review. Alabi Rashed, Omar Youssef, Helena Orell, Alhadi Almangush, and Antti Makitie drafted the manuscript. Akhiro Homma, Robert Tekes, Fernando Lopez, Remco de Bree, Juan Rodrigo, and Alfio Ferlito were involved in commenting and revising the manuscript. All authors approved the final version.

**Discloures.** Antti A. Makitie, Rasheed Omobolaji Alabi, Helena Orell, Omar Youssef, Alhadi Almangush, Akhiro Homma, Robert Takes, Fernando López, Remco de Bree, Juan P Rodrigo, Alfio Ferlito all have nothing to disclose.

**Compliance with Ethics Guidelines.** This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Data Availability. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Chow LQM. Head and Neck Cancer. N Engl J Med. 2020;382:60–72. https://doi.org/10.1056/NEJMr1715715.

2. World Health Organization. Cancer: fact sheet. 2018. https://www.who.int/en/news-room/fact-sheets/detail/cancer. Accessed 16 June 2020.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clinicians. 2020;70:7–30. https://doi.org/10.3322/caac.21590.

4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(2018):394–424. https://doi.org/10.3322/caac.21492.

5. Muthanandam S, Muthu J. Understanding cachexia in head and neck cancer. Asia Pac J Oncol Nurs. 2021;27:527–38. https://doi.org/10.4103/apjon.apjon-2145.

6. Langius JAE, Doornaert P, Spreeuwemberg MD, Langendijk JA, Leemans CR, van der Schuermen MAE. Radiotherapy on the neck nodes predicts severe weight loss in patients with early stage laryngeal cancer. Radiother Oncol. 2010;97:80–5. https://doi.org/10.1016/j.radonc.2010.02.017.

7. Unsal D, Mentes B, Akmansu M, Uner A, Oguz M, Pak Y. Evaluation of nutritional status in cancer patients receiving radiotherapy: a prospective study. Am J Clin Oncol. 2006;29:183–8. https://doi.org/10.1097/01.coc.0000198745.94757.ee.

8. Blauwhoff-Buskeromolen S, Versteeg KS, de van der Schuermen MAE, den Braver NR, Berkhof J, Langius JAE, Verheul HMW. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol. 2016;34:1339–44. https://doi.org/10.1200/JCO.2015.63.6043.

9. Evans WJ, Morley JE, Argilés J, Bales C, Baracov V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Locs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Scholz A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr. 2008;27:793–9. https://doi.org/10.1016/j.clnu.2008.06.013.

10. Roeland EJ, Bohlke K, Baracov VE, Bruera E, del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38:2438–53. https://doi.org/10.1200/JCO.20.00611.

11. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracov VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95. https://doi.org/10.1016/S1470-2045(10)70218-7.

12. Nakajima N. Differential diagnosis of cachexia and refractory cachexia and the impact of appropriate nutritional intervention for cachexia on survival in terminal cancer patients. Nutrients. 2021;13:915. https://doi.org/10.3390/nu13030915.

13. Prado CMM, Baracov VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920–6. https://doi.org/10.1158/1078-0432.CCR-08-2242.

14. Orell-Kotikangas H, Österlund P, Mäkkie O, Saariluht K, Ravasco P, Schwab U, Mäkkie AA. Cachexia at diagnosis is associated with poor survival in head
and neck cancer patients. Acta Otolaryngol. 2017;137:778–85. https://doi.org/10.1080/00016489.2016.1277263.

15. Economopoulou P, de Bree R, Kotsantis I, Psyrri A. Diagnostic tumor markers in head and neck squamous cell carcinoma (HNSCC) in the clinical setting. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00827.

16. Darwin D, Castelino R, Babu G, Asan M, Sarkar A, Shaktivel S. Oral equilibrium in cachexia. Asia Pac J Oncol Nurs. 2021;8:519–26.

17. National Institute of Health. Study quality assessment tools, United States. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 13 May 2020.

18. Phillips CS, Becker H. Systematic review: expressive arts interventions to address psychosocial stress in healthcare workers. J Adv Nurs. 2019;75:2285–98. https://doi.org/10.1111/jan.14043.

19. Halpern SH, Douglas MJ, editors. Evidence-based obstetric anesthesia. Oxford: Blackwell Publishing Ltd; 2005. https://doi.org/10.1002/97804709988343.

20. Chung JH, Kang DH, Jo JK, Lee SW. Assessing the quality of randomized controlled trials published in the Journal of Korean Medical Science from 1986 to 2011. J Korean Med Sci. 2012;27:973. https://doi.org/10.3346/jkms.2012.27.9.973.

21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. https://doi.org/10.1016/0197-2456(95)00134-4.

22. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC. Cochrane Bias Methods Group, Cochrane Statistical Methods Group, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928. https://doi.org/10.1136/bmj.d5928.

23. Mantovani G. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomark Prev. 2006;15:1030–4. https://doi.org/10.1158/1055-9065.EPI-05-0538.

24. Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, Couch M. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck. 2008;30:67–74. https://doi.org/10.1002/hed.20662.

25. Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Dessi M, Panzone F, Contu P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15:200–11. https://doi.org/10.1634/theoncologist.2009-0153.

26. Madeddu C, Dessi M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Macciò A, Mantovani G. Randomized phase III clinical trial of a combined treatment with corticosteroids ± celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr. 2012;31:176–82. https://doi.org/10.1016/j.clnu.2011.10.005.

27. Yeh K-Y, Wang H-M, Chang JW-C, Huang J-S, Lai C-H, Lan Y-J, Wu T-H, Chang P-H, Wang H, Wu C-J, Hsia S, Wang C-H. Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2013;116:41–8. https://doi.org/10.1016/j.oooo.2013.01.015.

28. Grote M, Mailhöfer C, Weigl M, Davies-Knorr P, Belka C. Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial. Radiat Oncol. 2018. https://doi.org/10.1186/s13014-018-1157-0.

29. Bar-Sela G, Zalman D, Semenysty V, Ballan E. The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study. Integr Cancer Ther. 2019;18:1534735419881498. https://doi.org/10.1177/1534735419881498.

30. Osmolak AM, Klatt-Cromwell CN, Price AM, Sanclernt JA, Krempl GA. Does perioperative oxandrolone improve nutritional status in patients with cancer-related cachexia related to head and neck carcinoma?, Laryngoscope Investigative. Otolaryngology. 2019;4:314–8. https://doi.org/10.1002/lio2.268.

31. Blum D, de Wolf-Linder S, Oberholzer R, Brändle M, Hundsberger T, Strasser F. Natural ghrelin in advanced cancer patients with cachexia, a case series. J Cachexia Sarcopenia Muscle. 2021;12:506–16. https://doi.org/10.1002/jcsm.12659.

32. Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Chang EY, Gourin CG, Der-Torossian H. Cancer cachexia update in head and neck cancer: pathophysiology and treatment: head and neck cancer cachexia. Head Neck. 2015;37:1057–72. https://doi.org/10.1002/hed.23696.
33. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23:8500–11. https://doi.org/10.1200/JCO.2005.01.8010.

34. Solheim TS, Fearon KCH, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review. Acta Oncol. 2013;52:6–17. https://doi.org/10.3109/0284186X.2012.724536.

35. Desport JC, Gory-Delabaere G, Blanc-Vincent MP, Bachmann P, Béal J, Benamouzig R, Colomb V, Kere D, Melchior JC, Nitenberg G, Raynard B, Schneider S, Senesse P. Standards, options and recommendations for the use of appetite stimulants in oncology (2000). Br J Cancer. 2003;89:S98–100. https://doi.org/10.1038/sj.bjc.6601090.

36. Couch M, Lai V, Cannon T, Guttridge D, Zanation A, George J, Hayes DN, Zeisel S, Shores C. Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck. 2007;29:401–11. https://doi.org/10.1002/hed.20447.

37. Gullett NP, Mazurak VC, Hebbar G, Ziegler TR. Nutritional interventions for cancer-induced cachexia. Curr Probl Cancer. 2011;35:58–90. https://doi.org/10.1016/j.currproblcancer.2011.01.001.

38. Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. Curr Oncol Rep. 2017;19:3. https://doi.org/10.1007/s11912-017-0562-0.

39. Mantovani G. Innovative treatment approach for cancer-related cachexia, anti-inflammatory & anti-allergy agents in medicinal. Chemistry. 2011;10:315–22. https://doi.org/10.2174/187152311797928153.

40. McCurdy B, Nejatinamini S, Debenham BJ, Álvarez-Camacho M, Kubrak C, Wismer WV, Mazurak VC. Meeting minimum ESPEN energy recommendations is not enough to maintain muscle mass in head and neck cancer patients. Nutrients. 2019;11:2743. https://doi.org/10.3390/nu11112743.

41. Almada-Correia I, Neves PM, Mákittie A, Ravasco P. Body composition evaluation in head and neck cancer patients: a review. Front Oncol. 2019;9:1112. https://doi.org/10.3389/fonc.2019.01112.

42. Müller-Richter U, Betz C, Hartmann S, Brands RC. Nutrition management for head and neck cancer patients improves clinical outcome and survival. Nutr Res. 2017;48:1–8. https://doi.org/10.1016/j.nutres.2017.08.007.
receiving chemotherapy. Br J Cancer. 2006;95:431–4. https://doi.org/10.1038/sj.bjc.6603280.

52. Pacelli F, Bossola M, Rosa F, Tortorelli AP, Papa V, Doglietto GB. Is malnutrition still a risk factor of postoperative complications in gastric cancer surgery? Clin Nutr. 2008;27:396–407. https://doi.org/10.1016/j.clnu.2008.03.002.

53. Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 2004;90:996–1002. https://doi.org/10.1038/sj.bjc.6601620.

54. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008;12:1193–201. https://doi.org/10.1007/s11605-008-0505-z.

55. Nicolini A, Ferrari P, Masoni MC, Fini M, Pagani S, Giampietro O, Carpi A. Malnutrition, anorexia and cachexia in cancer patients: a mini-review on pathogenesis and treatment. Biomed Pharmacother. 2013;67:807–17. https://doi.org/10.1016/j.biopha.2013.08.005.

56. Scolapio J, Picco M, Tarosa V. Enteral versus parenteral nutrition: the patient’s preference. J Parent Enter Nutr. 2002;26:248–50. https://doi.org/10.1177/0148607102026004248.

57. Curtin P, Akbar A, Kramer H, Iqbal A, Markossian T. The status of nutritional management guidelines for head and neck cancer patients. Cureus. 2020. https://doi.org/10.7759/cureus.11309.

58. Balstad TR, Solheim TS, Strasser F, Kaasa S, Bye A. Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review. Crit Rev Oncol Hematol. 2014;91:210–21. https://doi.org/10.1016/j.critrevonc.2014.02.005.

59. Maddocks M, Murton AJ, Wilcock A. Therapeutic exercise in cancer cachexia. Crit Rev Oncogenes. 2012;17:285–92. https://doi.org/10.1615/CritRevOncog.v17.i3.60.

60. Grande AJ, Silva V, Sawaris Neto L, Teixeira Basmage JP, Peccin MS, Maddocks M. Exercise for cancer cachexia in adults. Cochrane Database Syst Rev. 2021. https://doi.org/10.1002/14651858.CD010804.pub3.

61. Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res. 2020;12:5597–605. https://doi.org/10.2147/CMAR.S261585.

62. Solís-Martínez O, Álvarez-Altamirano K, Cardenas D, Trujillo-Cabrera Y, Fuchs-Tarlovsky V. Cancer cachexia affects patients with head and neck cancer in all stages of disease: a prospective cross-sectional study. Nutr Cancer. 2021. https://doi.org/10.1080/01635581.2020.1869792.